ID   MARK1_HUMAN             Reviewed;         795 AA.
AC   Q9P0L2; D3DTB0; D3DTB1; Q2HIY1; Q5VTF9; Q5VTG0; Q96SW9; Q9P251;
DT   12-APR-2005, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   12-OCT-2022, entry version 189.
DE   RecName: Full=Serine/threonine-protein kinase MARK1;
DE            EC=2.7.11.1;
DE            EC=2.7.11.26;
DE   AltName: Full=MAP/microtubule affinity-regulating kinase 1;
DE   AltName: Full=PAR1 homolog c;
DE            Short=Par-1c;
DE            Short=Par1c;
GN   Name=MARK1 {ECO:0000312|HGNC:HGNC:6896};
GN   Synonyms=KIAA1477 {ECO:0000312|EMBL:BAA96001.1}, MARK
GN   {ECO:0000312|EMBL:AAF72103.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ACTIVITY REGULATION,
RP   PHOSPHORYLATION AT THR-215, AND MUTAGENESIS OF THR-215.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J.,
RA   Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily,
RT   including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAF72103.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Zhou H.J., Huang X.W., Zhou Y., Hu S.L., Yuan J.G., Qiang B.Q.;
RT   "Cloning and isolating human MARK.";
RL   Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000305, ECO:0000312|EMBL:BAA96001.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain {ECO:0000269|PubMed:10819331};
RX   PubMed=10819331; DOI=10.1093/dnares/7.2.143;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:143-150(2000).
RN   [4] {ECO:0000305, ECO:0000312|EMBL:BAB55152.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6] {ECO:0000305, ECO:0000312|EMBL:AAF72103.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8] {ECO:0000305}
RP   TISSUE SPECIFICITY.
RX   PubMed=9108484; DOI=10.1016/s0092-8674(00)80208-1;
RA   Drewes G., Ebneth A., Preuss U., Mandelkow E.-M., Mandelkow E.;
RT   "MARK - a novel family of protein kinases that phosphorylate microtubule-
RT   associated proteins and trigger microtubule disruption.";
RL   Cell 89:297-308(1997).
RN   [9]
RP   NEUROFIBRILLARY TANGLES IN ALZHEIMER BRAIN.
RX   PubMed=11089574; DOI=10.1093/jnen/59.11.966;
RA   Chin J.Y., Knowles R.B., Schneider A., Drewes G., Mandelkow E.M.,
RA   Hyman B.T.;
RT   "Microtubule-affinity regulating kinase (MARK) is tightly associated with
RT   neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy
RT   transfer study.";
RL   J. Neuropathol. Exp. Neurol. 59:966-971(2000).
RN   [10]
RP   FUNCTION.
RX   PubMed=11433294; DOI=10.1038/35083016;
RA   Sun T.-Q., Lu B., Feng J.-J., Reinhard C., Jan Y.N., Fantl W.J.,
RA   Williams L.T.;
RT   "PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt
RT   signalling.";
RL   Nat. Cell Biol. 3:628-636(2001).
RN   [11]
RP   PHOSPHORYLATION AT THR-208, ACTIVITY REGULATION, AND FUNCTION.
RX   PubMed=17573348; DOI=10.1074/jbc.m700590200;
RA   Kojima Y., Miyoshi H., Clevers H.C., Oshima M., Aoki M., Taketo M.M.;
RT   "Suppression of tubulin polymerization by the LKB1-microtubule-associated
RT   protein/microtubule affinity-regulating kinase signaling.";
RL   J. Biol. Chem. 282:23532-23540(2007).
RN   [12]
RP   POSSIBLE INVOLVEMENT IN AUTISM.
RX   PubMed=18492799; DOI=10.1093/hmg/ddn154;
RA   Maussion G., Carayol J., Lepagnol-Bestel A.M., Tores F., Loe-Mie Y.,
RA   Milbreta U., Rousseau F., Fontaine K., Renaud J., Moalic J.M., Philippi A.,
RA   Chedotal A., Gorwood P., Ramoz N., Hager J., Simonneau M.;
RT   "Convergent evidence identifying MAP/microtubule affinity-regulating kinase
RT   1 (MARK1) as a susceptibility gene for autism.";
RL   Hum. Mol. Genet. 17:2541-2551(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-5 AND SER-403, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-588, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   REVIEW.
RX   PubMed=19559622; DOI=10.1016/j.tibs.2009.03.008;
RA   Matenia D., Mandelkow E.M.;
RT   "The tau of MARK: a polarized view of the cytoskeleton.";
RL   Trends Biochem. Sci. 34:332-342(2009).
RN   [18]
RP   REVIEW.
RX   PubMed=20071654; DOI=10.1096/fj.09-148064;
RA   Marx A., Nugoor C., Panneerselvam S., Mandelkow E.;
RT   "Structure and function of polarity-inducing kinase family MARK/Par-1
RT   within the branch of AMPK/Snf1-related kinases.";
RL   FASEB J. 24:1637-1648(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   FUNCTION, INTERACTION WITH MAPT, AND SUBCELLULAR LOCATION.
RX   PubMed=23666762; DOI=10.1007/s12017-013-8232-3;
RA   Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G.,
RA   Landegren U., Sunnemark D., Kamali-Moghaddam M.;
RT   "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in
RT   Alzheimer's disease.";
RL   NeuroMolecular Med. 15:458-469(2013).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 45-371.
RX   PubMed=16803889; DOI=10.1074/jbc.m604865200;
RA   Marx A., Nugoor C., Muller J., Panneerselvam S., Timm T., Bilang M.,
RA   Mylonas E., Svergun D.I., Mandelkow E.M., Mandelkow E.;
RT   "Structural variations in the catalytic and ubiquitin-associated domains of
RT   microtubule-associated protein/microtubule affinity regulating kinase
RT   (MARK) 1 and MARK2.";
RL   J. Biol. Chem. 281:27586-27599(2006).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 683-795, DOMAIN KA1, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF ARG-698; ARG-701; 771-ARG--LYS-773 AND
RP   773-LYS-ARG-774.
RX   PubMed=21145462; DOI=10.1016/j.cell.2010.11.028;
RA   Moravcevic K., Mendrola J.M., Schmitz K.R., Wang Y.H., Slochower D.,
RA   Janmey P.A., Lemmon M.A.;
RT   "Kinase associated-1 domains drive MARK/PAR1 kinases to membrane targets by
RT   binding acidic phospholipids.";
RL   Cell 143:966-977(2010).
RN   [25]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-233; THR-355; MET-530; LEU-578 AND
RP   GLY-691.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved
CC       in cell polarity and microtubule dynamics regulation. Phosphorylates
CC       DCX, MAP2 and MAP4. Phosphorylates the microtubule-associated protein
CC       MAPT/TAU (PubMed:23666762). Involved in cell polarity by
CC       phosphorylating the microtubule-associated proteins MAP2, MAP4 and
CC       MAPT/TAU at KXGS motifs, causing detachment from microtubules, and
CC       their disassembly. Involved in the regulation of neuronal migration
CC       through its dual activities in regulating cellular polarity and
CC       microtubule dynamics, possibly by phosphorylating and regulating DCX.
CC       Also acts as a positive regulator of the Wnt signaling pathway,
CC       probably by mediating phosphorylation of dishevelled proteins (DVL1,
CC       DVL2 and/or DVL3). {ECO:0000269|PubMed:11433294,
CC       ECO:0000269|PubMed:17573348, ECO:0000269|PubMed:23666762}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:14976552};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:14976552};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[tau protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [tau protein]; Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA-
CC         COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[tau protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[tau protein]; Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703,
CC         Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.26;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Inhibited by phosphorylation at Ser-219 (By
CC       similarity). Activated by phosphorylation on Thr-215. {ECO:0000250,
CC       ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:17573348}.
CC   -!- SUBUNIT: Interacts with MAPT/TAU. {ECO:0000269|PubMed:23666762}.
CC   -!- INTERACTION:
CC       Q9P0L2; P05067: APP; NbExp=3; IntAct=EBI-968587, EBI-77613;
CC       Q9P0L2; P63172: DYNLT1; NbExp=3; IntAct=EBI-968587, EBI-1176455;
CC       Q9P0L2; Q0VD86: INCA1; NbExp=3; IntAct=EBI-968587, EBI-6509505;
CC       Q9P0L2; O95988: TCL1B; NbExp=5; IntAct=EBI-968587, EBI-727338;
CC       Q9P0L2; Q8IY57-5: YAF2; NbExp=3; IntAct=EBI-968587, EBI-12111538;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21145462};
CC       Peripheral membrane protein {ECO:0000269|PubMed:21145462}. Cytoplasm,
CC       cytoskeleton {ECO:0000250}. Cytoplasm {ECO:0000269|PubMed:23666762}.
CC       Cell projection, dendrite {ECO:0000269|PubMed:23666762}. Note=Appears
CC       to localize to an intracellular network. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9P0L2-1; Sequence=Displayed;
CC       Name=2 {ECO:0000305};
CC         IsoId=Q9P0L2-2; Sequence=VSP_051702, VSP_051704;
CC       Name=3 {ECO:0000305};
CC         IsoId=Q9P0L2-3; Sequence=VSP_051703, VSP_051704;
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle, brain,
CC       fetal brain and fetal kidney. {ECO:0000269|PubMed:9108484}.
CC   -!- DOMAIN: The UBA domain does not seem to bind ubiquitin and ubiquitin-
CC       like and might play a role in regulating the enzyme conformation and
CC       localization. Activation of the kinase activity following
CC       phosphorylation at Thr-208 is accompanied by a conformational change
CC       that alters the orientation of the UBA domain with respect to the
CC       catalytic domain (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The KA1 domain mediates binding to phospholipids and targeting
CC       to membranes. Binds phosphatidic acid (PA), phosphatidylserine (PtdSer)
CC       and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2).
CC       {ECO:0000269|PubMed:21145462}.
CC   -!- PTM: Phosphorylation at Thr-613 by PRKCZ/aPKC in polarized epithelial
CC       cells inhibits the kinase activity (By similarity). Phosphorylated at
CC       Thr-215 by STK11/LKB1 in complex with STE20-related adapter-alpha
CC       (STRADA) pseudo kinase and CAB39. Phosphorylation at Thr-215 by TAOK1
CC       activates the kinase activity, leading to phosphorylation and
CC       detachment of MAPT/TAU from microtubules. Phosphorylation at Ser-219 by
CC       GSK3-beta (GSK3B) inhibits the kinase activity. {ECO:0000250,
CC       ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:17573348}.
CC   -!- DISEASE: Note=Genetic variations in MARK1 may be associated with
CC       susceptibility to autism. MARK1 is overexpressed in the prefrontal
CC       cortex of patients with autism and causes changes in the function of
CC       cortical dendrites.
CC   -!- MISCELLANEOUS: Phosphorylation of MAPT/tau by MARK1 could play a role
CC       in early steps of Alzheimer disease. Pathological aggregation of
CC       MAPT/tau to neurofibrillary tangles, filamentous structures consisting
CC       of paired helical filaments (PHFs), is one of the hallmarks of
CC       Alzheimer disease. Hyperphosphorylation by MARK1 could be the initial
CC       step for this abnormal aggregation of tau in Alzheimer disease and
CC       animal models of tauopathy (PubMed:11089574).
CC       {ECO:0000305|PubMed:11089574}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. SNF1 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA96001.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAB55152.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF154845; AAF72103.1; -; mRNA.
DR   EMBL; AB040910; BAA96001.1; ALT_INIT; mRNA.
DR   EMBL; AK027493; BAB55152.1; ALT_FRAME; mRNA.
DR   EMBL; AC096640; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL592406; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471100; EAW93299.1; -; Genomic_DNA.
DR   EMBL; CH471100; EAW93300.1; -; Genomic_DNA.
DR   EMBL; CH471100; EAW93302.1; -; Genomic_DNA.
DR   EMBL; BC113869; AAI13870.1; -; mRNA.
DR   EMBL; BC114478; AAI14479.1; -; mRNA.
DR   CCDS; CCDS31029.2; -. [Q9P0L2-1]
DR   CCDS; CCDS65789.1; -. [Q9P0L2-3]
DR   RefSeq; NP_001273057.1; NM_001286128.1. [Q9P0L2-3]
DR   RefSeq; NP_061120.3; NM_018650.4. [Q9P0L2-1]
DR   PDB; 2HAK; X-ray; 2.60 A; A/B/C/D/E/F/G/H=45-371.
DR   PDB; 3OSE; X-ray; 1.70 A; A=683-795.
DR   PDB; 6C9D; X-ray; 2.50 A; A/B=45-795.
DR   PDBsum; 2HAK; -.
DR   PDBsum; 3OSE; -.
DR   PDBsum; 6C9D; -.
DR   AlphaFoldDB; Q9P0L2; -.
DR   SASBDB; Q9P0L2; -.
DR   SMR; Q9P0L2; -.
DR   BioGRID; 110309; 54.
DR   DIP; DIP-39777N; -.
DR   IntAct; Q9P0L2; 38.
DR   MINT; Q9P0L2; -.
DR   STRING; 9606.ENSP00000483424; -.
DR   BindingDB; Q9P0L2; -.
DR   ChEMBL; CHEMBL5940; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9P0L2; -.
DR   GuidetoPHARMACOLOGY; 2097; -.
DR   CarbonylDB; Q9P0L2; -.
DR   iPTMnet; Q9P0L2; -.
DR   PhosphoSitePlus; Q9P0L2; -.
DR   BioMuta; MARK1; -.
DR   DMDM; 124056494; -.
DR   EPD; Q9P0L2; -.
DR   jPOST; Q9P0L2; -.
DR   MassIVE; Q9P0L2; -.
DR   MaxQB; Q9P0L2; -.
DR   PaxDb; Q9P0L2; -.
DR   PeptideAtlas; Q9P0L2; -.
DR   PRIDE; Q9P0L2; -.
DR   ProteomicsDB; 83571; -. [Q9P0L2-1]
DR   ProteomicsDB; 83572; -. [Q9P0L2-2]
DR   ProteomicsDB; 83573; -. [Q9P0L2-3]
DR   Antibodypedia; 2072; 454 antibodies from 32 providers.
DR   DNASU; 4139; -.
DR   Ensembl; ENST00000366917.6; ENSP00000355884.5; ENSG00000116141.17. [Q9P0L2-1]
DR   Ensembl; ENST00000366918.8; ENSP00000355885.4; ENSG00000116141.17. [Q9P0L2-3]
DR   GeneID; 4139; -.
DR   KEGG; hsa:4139; -.
DR   MANE-Select; ENST00000366917.6; ENSP00000355884.5; NM_018650.5; NP_061120.3.
DR   UCSC; uc001hmm.6; human. [Q9P0L2-1]
DR   CTD; 4139; -.
DR   DisGeNET; 4139; -.
DR   GeneCards; MARK1; -.
DR   HGNC; HGNC:6896; MARK1.
DR   HPA; ENSG00000116141; Low tissue specificity.
DR   MIM; 606511; gene.
DR   neXtProt; NX_Q9P0L2; -.
DR   OpenTargets; ENSG00000116141; -.
DR   PharmGKB; PA30639; -.
DR   VEuPathDB; HostDB:ENSG00000116141; -.
DR   eggNOG; KOG0586; Eukaryota.
DR   GeneTree; ENSGT00940000157560; -.
DR   InParanoid; Q9P0L2; -.
DR   OMA; DWVIFED; -.
DR   PhylomeDB; Q9P0L2; -.
DR   TreeFam; TF315213; -.
DR   PathwayCommons; Q9P0L2; -.
DR   SignaLink; Q9P0L2; -.
DR   SIGNOR; Q9P0L2; -.
DR   BioGRID-ORCS; 4139; 14 hits in 1111 CRISPR screens.
DR   ChiTaRS; MARK1; human.
DR   EvolutionaryTrace; Q9P0L2; -.
DR   GeneWiki; MARK1; -.
DR   GenomeRNAi; 4139; -.
DR   Pharos; Q9P0L2; Tchem.
DR   PRO; PR:Q9P0L2; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q9P0L2; protein.
DR   Bgee; ENSG00000116141; Expressed in cortical plate and 177 other tissues.
DR   ExpressionAtlas; Q9P0L2; baseline and differential.
DR   Genevisible; Q9P0L2; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0070300; F:phosphatidic acid binding; IDA:UniProtKB.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0051654; P:establishment of mitochondrion localization; ISS:ARUK-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; ISS:ARUK-UCL.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IDA:ARUK-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:ARUK-UCL.
DR   GO; GO:0001764; P:neuron migration; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; NAS:ARUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:ARUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050773; P:regulation of dendrite development; ISS:ARUK-UCL.
DR   GO; GO:0010975; P:regulation of neuron projection development; ISS:ARUK-UCL.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR001772; KA1_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033627; MARK1.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR015940; UBA.
DR   PANTHER; PTHR24346:SF21; PTHR24346:SF21; 1.
DR   Pfam; PF02149; KA1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00627; UBA; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50032; KA1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50030; UBA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Autism;
KW   Autism spectrum disorder; Cell membrane; Cell projection; Cytoplasm;
KW   Cytoskeleton; Kinase; Lipid-binding; Magnesium; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Wnt signaling pathway.
FT   CHAIN           1..795
FT                   /note="Serine/threonine-protein kinase MARK1"
FT                   /id="PRO_0000086298"
FT   DOMAIN          60..311
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          325..370
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   DOMAIN          746..795
FT                   /note="KA1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00565"
FT   REGION          1..40
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          377..495
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          539..700
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        22..40
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        381..423
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        444..459
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        549..563
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        583..614
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        679..700
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        182
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H0K1,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-
FT                   ProRule:PRU10027"
FT   BINDING         66..74
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q9H0K1,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         89
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:O08678,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         5
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         208
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:17573348"
FT   MOD_RES         215
FT                   /note="Phosphothreonine; by LKB1 and TAOK1"
FT                   /evidence="ECO:0000269|PubMed:14976552"
FT   MOD_RES         219
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:O08678"
FT   MOD_RES         382
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VHJ5"
FT   MOD_RES         390
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VHJ5"
FT   MOD_RES         393
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VHJ5"
FT   MOD_RES         403
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         423
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VHJ5"
FT   MOD_RES         444
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08678"
FT   MOD_RES         475
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VHJ5"
FT   MOD_RES         588
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         613
FT                   /note="Phosphothreonine; by PKC/PRKCZ"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         666
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8VHJ5"
FT   VAR_SEQ         1..135
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_051702"
FT   VAR_SEQ         120..141
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10819331"
FT                   /id="VSP_051703"
FT   VAR_SEQ         663..677
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10819331,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_051704"
FT   VARIANT         233
FT                   /note="Y -> C (in a gastric adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040760"
FT   VARIANT         355
FT                   /note="N -> T (in an ovarian serous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040761"
FT   VARIANT         530
FT                   /note="V -> M (in dbSNP:rs56212551)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040762"
FT   VARIANT         578
FT                   /note="P -> L (in dbSNP:rs55691439)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040763"
FT   VARIANT         645
FT                   /note="R -> G (in dbSNP:rs12123778)"
FT                   /id="VAR_030018"
FT   VARIANT         691
FT                   /note="E -> G (in dbSNP:rs55688276)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040764"
FT   MUTAGEN         215
FT                   /note="T->A: Prevents phosphorylation and activation by
FT                   STK11/LKB1 complex."
FT                   /evidence="ECO:0000269|PubMed:14976552"
FT   MUTAGEN         215
FT                   /note="T->E: Constitutively active."
FT                   /evidence="ECO:0000269|PubMed:14976552"
FT   MUTAGEN         698
FT                   /note="R->S: Impairs phospholipid-binding, targeting to
FT                   membrane and vesicle-binding; when associated with S-701."
FT                   /evidence="ECO:0000269|PubMed:21145462"
FT   MUTAGEN         701
FT                   /note="R->S: Impairs phospholipid-binding, targeting to
FT                   membrane and vesicle-binding; when associated with S-698."
FT                   /evidence="ECO:0000269|PubMed:21145462"
FT   MUTAGEN         771..773
FT                   /note="RFK->AFA: Impairs phospholipid-binding."
FT                   /evidence="ECO:0000269|PubMed:21145462"
FT   CONFLICT        16
FT                   /note="E -> V (in Ref. 2; AAF72103)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        20
FT                   /note="S -> T (in Ref. 2; AAF72103)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        522
FT                   /note="D -> N (in Ref. 4; BAB55152)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        544
FT                   /note="V -> A (in Ref. 4; BAB55152)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        763
FT                   /note="P -> A (in Ref. 4; BAB55152)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        794
FT                   /note="K -> M (in Ref. 3; BAA96001)"
FT                   /evidence="ECO:0000305"
FT   STRAND          55..57
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   STRAND          60..68
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   STRAND          70..79
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   TURN            80..82
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   STRAND          85..92
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           93..95
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           98..111
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   STRAND          122..127
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   STRAND          129..136
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           146..151
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           156..175
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           185..187
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   STRAND          188..190
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   STRAND          196..198
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           201..203
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           220..222
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           225..228
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           236..252
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           262..271
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           282..291
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   TURN            296..298
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           302..305
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           309..312
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   STRAND          316..318
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           333..341
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           346..355
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           360..368
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   TURN            706..708
FT                   /evidence="ECO:0007829|PDB:6C9D"
FT   HELIX           714..727
FT                   /evidence="ECO:0007829|PDB:3OSE"
FT   STRAND          731..736
FT                   /evidence="ECO:0007829|PDB:3OSE"
FT   STRAND          739..745
FT                   /evidence="ECO:0007829|PDB:3OSE"
FT   TURN            747..750
FT                   /evidence="ECO:0007829|PDB:3OSE"
FT   STRAND          753..762
FT                   /evidence="ECO:0007829|PDB:3OSE"
FT   HELIX           763..765
FT                   /evidence="ECO:0007829|PDB:3OSE"
FT   STRAND          767..777
FT                   /evidence="ECO:0007829|PDB:3OSE"
FT   HELIX           779..792
FT                   /evidence="ECO:0007829|PDB:3OSE"
SQ   SEQUENCE   795 AA;  89003 MW;  71BF6EB76912631B CRC64;
     MSARTPLPTV NERDTENHTS VDGYTEPHIQ PTKSSSRQNI PRCRNSITSA TDEQPHIGNY
     RLQKTIGKGN FAKVKLARHV LTGREVAVKI IDKTQLNPTS LQKLFREVRI MKILNHPNIV
     KLFEVIETEK TLYLVMEYAS GGEVFDYLVA HGRMKEKEAR AKFRQIVSAV QYCHQKYIVH
     RDLKAENLLL DGDMNIKIAD FGFSNEFTVG NKLDTFCGSP PYAAPELFQG KKYDGPEVDV
     WSLGVILYTL VSGSLPFDGQ NLKELRERVL RGKYRIPFYM STDCENLLKK LLVLNPIKRG
     SLEQIMKDRW MNVGHEEEEL KPYTEPDPDF NDTKRIDIMV TMGFARDEIN DALINQKYDE
     VMATYILLGR KPPEFEGGES LSSGNLCQRS RPSSDLNNST LQSPAHLKVQ RSISANQKQR
     RFSDHAGPSI PPAVSYTKRP QANSVESEQK EEWDKDVARK LGSTTVGSKS EMTASPLVGP
     ERKKSSTIPS NNVYSGGSMA RRNTYVCERT TDRYVALQNG KDSSLTEMSV SSISSAGSSV
     ASAVPSARPR HQKSMSTSGH PIKVTLPTIK DGSEAYRPGT TQRVPAASPS AHSISTATPD
     RTRFPRGSSS RSTFHGEQLR ERRSVAYNGP PASPSHETGA FAHARRGTST GIISKITSKF
     VRRDPSEGEA SGRTDTSRST SGEPKERDKE EGKDSKPRSL RFTWSMKTTS SMDPNDMMRE
     IRKVLDANNC DYEQKERFLL FCVHGDARQD SLVQWEMEVC KLPRLSLNGV RFKRISGTSI
     AFKNIASKIA NELKL
//
